

China Construction Machinery

Assessing the impact of the European Commission's anti-dumping investigation against China-made AWP

What is new? The European Commission announced yesterday (13 Nov) that it will initiate an anti-dumping proceeding concerning imports of mobile access equipment (MAE, or AWP) from China ([source](#)). While this looks negative to the Chinese AWP manufacturers at first glance, we think the estimated investigation time of 13-14 months will provide the Chinese manufacturers with time to take measures to mitigate the potential impact. For instance, they can localize their AWP production overseas to avoid the potential duties. Besides, given that different tariffs may be applied, manufacturers with more experience in dealing with the investigation will have the chance to fight for lower tariffs.

■ **Details of the anti-dumping investigation:** The complaint was lodged on 29 Sep 2023 by the "Coalition to restore a level-playing field in the EU Mobile Access Equipment Sector". The product under investigation is MAE designed for the lifting of persons and self-propelled, with a max. working height of 6 meters or more, and pre-assembled or read-to-assemble sections. The investigation of dumping and injury will cover the period from 1 Oct 2022 to 30 Sep 2023, while the examination of trends relevant for the assessment of injury will cover the period from 1 Jan 2020 to 30 Sep 2023. The investigation will be concluded normally within 13 months, but not more than 14 months of the date of publication of the notice (13 Nov).

Implications to major Chinese AWP manufacturers:

- **Zhejiang Dingli (603338 CH, BUY, TP: RMB70)** – Dingli generated 70% of revenue from overseas in 3Q23. Of the overseas revenue, both Europe and the US accounted for 35% (each). Currently, Dingli is subject to the anti-dumping (31.54%) and countervailing duties (11.95%) in the US but the duties are much lower than other Chinese players. Most importantly, Dingli has managed to achieve good revenue in the US market even with the duties. We believe Dingli's rich experience in dealing with the anti-dumping investigation will help it minimize the potential impact in the case of EU.
- **Zoomlion (1157 HK, TP: HK\$6.35 / 000157 CH, TP: RMB7.3, BUY)** – AWP sales overseas accounted for only 5% of Zoomlion's total revenue in 3Q23, and we believe the AWP sales in the EU is not significant. Therefore, we believe the potential impact will be limited. Besides, Zoomlion can leverage its overseas production bases (e.g. Italy, Germany, Mexico) to establish AWP capacity.
- **Jiangsu Hengli (601100 CH, BUY, TP: RMB83)** – Hengli offers hydraulic components and motors to both Chinese and overseas AWP manufacturers. Given that components are not the targets of the investigation, the potential impact on Hengli is insignificant, in our view.

OUTPERFORM
(Maintain)

China Capital Goods

Wayne Fung, CFA

(852) 3900 0826

waynefung@cmbi.com.hk

Related Reports

1. SANY International (631 HK, BUY) – Weak revenue growth in the price; overseas growth story still intact – 2 Nov 2023 ([link](#))
2. China Construction Machinery & HDT – 3Q23 earnings review: Weichai & Zoomlion beat; SANY Heavy & Jiangsu Hengli miss – 31 Oct 2023
3. Zhejiang Dingli (603338 CH, BUY) – 3Q23 earnings +53% YoY; A clean beat on a surprising margin expansion – 30 Oct 2023 ([link](#))
4. China Heavy Duty Truck – Is the growth of natural gas truck sales sustainable? – 24 Oct 2023 ([link](#))
5. Weichai Power (2338 HK / 000338 CH, BUY) – 3Q23 earnings surged 120-200% YoY; Strong gas trucks sales continue to be the key driver – 16 Oct 2023 ([link](#) for H) ([link](#) for A)
6. SANYI (631 HK, BUY) – Net profit in 2Q23 +19% YoY; Higher R&D spending but still a set of good quality results – 1 Sep 2023 ([link](#))
7. SANY Heavy (600031 CH, HOLD) – 2Q23 net profit +81% but largely due to low base & FX gain; Staying cautious on export – 31 Aug 2023 ([link](#))
8. Zoomlion (1157 HK / 000157 CH, BUY) – 2Q23 net profit +50% YoY in line with expectations – 31 Aug 2023 ([link](#))
9. Jiangsu Hengli (601100 CH, BUY) – 2Q23 earnings +24%; Gross margin below expectations but likely rebounds – 29 Aug 2023 ([link](#))

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.